Zertomibgene cazparvovec - Tenaya Therapeutics
Alternative Names: TN-201Latest Information Update: 12 Jun 2026
At a glance
- Originator Tenaya Therapeutics
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin-binding protein C replacements
-
Orphan Drug Status
Yes - Hypertrophic cardiomyopathy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hypertrophic cardiomyopathy
Most Recent Events
- 03 Jun 2026 US FDA accepts Rare Disease Evidence Principles (RDEP) process for Zertomibgene cazparvovec for Hypertrophic cardiomyopathy (In children) in USA
- 03 Jun 2026 Zertomibgene cazparvovec - Tenaya Therapeutics receives Priority Medicine (PRIME) status for Hypertrophic cardiomyopathy in European Union
- 03 Jun 2026 Efficacy, pharmacodynamics and adverse events data from a phase I/II MyPEAK-1 trial in hypertrophic cardiomyopathy released by Tenaya Therapeutics